WO2021007703A1 - Procédé de préparation de liraglutide par synthèse de peptides en phase solide - Google Patents

Procédé de préparation de liraglutide par synthèse de peptides en phase solide Download PDF

Info

Publication number
WO2021007703A1
WO2021007703A1 PCT/CN2019/095783 CN2019095783W WO2021007703A1 WO 2021007703 A1 WO2021007703 A1 WO 2021007703A1 CN 2019095783 W CN2019095783 W CN 2019095783W WO 2021007703 A1 WO2021007703 A1 WO 2021007703A1
Authority
WO
WIPO (PCT)
Prior art keywords
fmoc
otbu
tbu
pbf
alanine
Prior art date
Application number
PCT/CN2019/095783
Other languages
English (en)
Inventor
Ivan Di BONAVENTURA
Runze HE
Original Assignee
Shanghai Space Peptides Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Space Peptides Pharmaceutical Co., Ltd. filed Critical Shanghai Space Peptides Pharmaceutical Co., Ltd.
Priority to PCT/CN2019/095783 priority Critical patent/WO2021007703A1/fr
Publication of WO2021007703A1 publication Critical patent/WO2021007703A1/fr

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • the present invention pertains to the field of biomedicine and the present invention is directed to a green and environment friendly synthetic method of liraglutide. Specifically, the present invention is directed a method for preparing liraglutide via a solid phase peptide synthesis.
  • Liraglutide is a long-acting, fatty acylated glucagon-like peptide-1 (GLP-1) analog administered subcutaneously, with antihyperglycemic activity. It is mainly used as a hypoglicemic agent and supplemental therapy in the treatment of DIABETES MELLITUS. Liraglutide's prolonged action and half-life of 11-15 hours are attributed to the attachment of the fatty acid palmitic acid to GLP-1 that reversibly binds to albumin. Albumin binding protects liraglutide from immediate degradation and elimination and causes GLP-1 to be released from albumin in a slow and consistent manner. As a widely used active pharmaceutical ingredient, Liraglutide is a derivative of human incretin glucagon-like peptide-1 (GLP-1) that is used as a long-acting glucagon-like peptide-1 receptor agonist.
  • GLP-1 human incretin glucagon-like peptide-1
  • Liraglutide is a 33 amino acid peptide with a chemical formula of C 172 H 265 N 43 O 51 and a molecular weight of 3751.262 g/mol, Liraglutide is also known as Victoza.
  • SPPS Solid Phase Peptide Synthesis
  • a method for preparing liraglutide by using a solid phase peptide synthesis SPPS
  • SPPS solid phase peptide synthesis
  • the method uses a Fmoc-Gly-resin with a Fmoc protective group as a carrier for the solid phase peptide synthesis, and after the completion of a deprotecting reaction of the Fmoc protective group, each of the reactions in the solid phase peptide synthesis of the liraglutide is washed with a mixture of DMF and ⁇ -valerolactone for several times, preferably 2-3 times.
  • the method comprises the following steps:
  • a branching lysine is used in a form selected from the group consisting of Fmoc-Lys (Alloc) -OH, Alloc-Lys (Fmoc) -OH, Fmoc-Lys (Mtt) -OH, Mtt-Lysine (Fmoc) -OH, Fmoc-Lysine (Dde) -OH, Dde-Lys (Fmoc) -OH, Fmoc-Lys (ivDde) -OH and ivDde-Lys (Fmoc) -OH;
  • the Fmoc-Gly-resin is selected from the group consisting of Fmoc-Gly-wang resin, Fmoc-Gly-2-CTC resin, Fmoc-Gly-Rink amide ProTide (LL) resin and Fmoc-Gly-ChemMatrix wang resin.
  • the coupling reagents in step a) are selected from the group consisting of ethyl 2-oxime cyanoacetate, N, N'diisopropylcarbodiimide, N, N'-dicyclohexylcarbodiimide, N, N-diisopropylethylamine, Benzotriazole-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate, Dicyclohexylcarbodiimide, and O- (7-Azabenzotriazol-1-yl) -N, N, N', N ⁇ -Tetramethyluronium Hexafluorophosphate, and any combinations thereof.
  • the Fmoc protective group of the Fmoc-Gly-resin in step a) is deprotected in the presence of a first mixture of piperidine or piperazine in DMF and ⁇ -valerolactone for 10-20 minutes at 50°C-90°C to obtain H-Gly-resin.
  • ⁇ -valerolactone is environment friendly green organic solvent which is widely used in food industry.
  • the combination reagents of the solvent mixture of ⁇ -valerolactone and DMF are suitable for peptides stable at a high temperature such as 90°C. Otherwise the peptides are easy to be degraded under such a high temperature.
  • the above first mixture has a volume ratio of piperidine or piperazine in DMF and ⁇ -valerolactone of between 1: 3 to 1: 5, preferably 1: 4. Further, in the mixture of DMF and ⁇ -valerolactone, DMF and ⁇ -valerolactone can be mixed with any volume ratio, preferably with a ratio range from 1: 4 to 4: 1.
  • the H-Gly-resin is further washed by a second mixture of DMF and ⁇ -valerolactone.
  • ⁇ -valerolactone presents 60 to 90 v/v %of the second mixture of DMF and ⁇ -valerolactone.
  • ⁇ -valerolactone is used to substitute 60%-90%of DMF, thereby reducing a large amount of DMF consumption in manufacture of liraglutide.
  • the step a) comprises the following sub-steps:
  • step a2) Washing the H-Gly-resin obtained in step a1) by a mixture of DMF and ⁇ -valerolactone;
  • each of the reactions in the solid phase peptide synthesis of the liraglutide is washed with the mixture of DMF and ⁇ -valerolactone for 2-3 times.
  • step b) the protective groups of Fmoc, Alloc, Mtt, ivDde and Dde are deprotected from the side chain of the branching lysine by washing with specific organic solvents.
  • the protective group Alloc of the side chain or the main chain of lysine is removed by washing with 0.1-0.4 fold of Pd (PPh 3 ) 4 and 10-30 folds of phenyl silane or borane dimethylamine under inert conditions for 45 min and repeated twice;
  • the protective group Mtt of the side chain of the lysine is removed by washing with a solution of TFA/TIS/DCM (1: 2: 97) for 30 minutes, then the solution is filtered, washed with: DCM, MeOH, DCM, 1%DIEA in DMF, and DMF. This method is repeated three times totally.
  • the protective group ivDde of the side chain of the lysine is removed by washing with a solution of 10%hydrazine monohydrate in DMF for 10 minutes and repeated three times with DMF.
  • the protective group Dde on the main chain of the lysine is removed by washing with a solution of 2%of hydrazine monohydrate in DMF for 3 minutes and this method is repeated 3 times.
  • the coupling reaction of the amino acid in the solid phase peptide synthesis of the liraglutide on the resin is carried out at a temperature of 50 to 90°C for 10 to 30 minutes depending on the temperature.
  • the resin is blown off with nitrogen before the cleavage reaction of step d) is carried out.
  • the cleavage reaction of step d) is carried out at a temperature between 10 to 50°C for 2-3 hours. Further, the purity of the trifluoroacetic acid added in the reaction is 95%.
  • the equivalents of the amino acids used are 2-3 times of the molar amount of the resin.
  • the crude liraglutide is purified by Pre-HPLC with a specific buffer, preferably acetonitrile and water with sodium dihydrogen phosphate buffer.
  • the purified Liraglutide solution is lyophilized at -50°C to -70°C for 18-48 hours.
  • Figure 1 is a schematic of liraglutide molecular structure.
  • Figure 2 is an HPLC analysis of Liraglutide prepared in Example 1.
  • Figure 3 is a Mass spectrum of Liraglutide prepared in Example 1.
  • Figure 4 is an HPLC analysis of Liraglutide prepared in Example 2.
  • Figure 5 is an HPLC analysis of Liraglutide prepared in Example 3.
  • Figure 6 is an HPLC analysis of Liraglutide prepared in Example 4.
  • Figure 7 is an HPLC analysis of Liraglutide prepared in Example 5.
  • the present invention provides a method for synthesizing liraglutide and to the synthetic method of liraglutide by solid phase peptide synthesis using Fmoc-Gly-Wang resin as a carrier.
  • the method is a green and environment friendly synthetic method due to the use of ⁇ -valerolactone to substitute 60%-90%of DMF.
  • the invention also has the advantages of high yield, less by-product and simple separation and purification, and its time gaining is better than the prior art, thus the method of the invention is suitable for pilot and industrial production.
  • Liraglutide shown in Figure 1 is 33 amino acids synthetic peptide.
  • the invention will now be described with reference to specific embodiments. It must be understood that these examples are merely illustrative of the invention and are not intended to limit the scope of the invention. Unless otherwise stated, the percentages are by volume. The experimental materials and reagents used in the examples below are available from commercially available sources unless otherwise specified.
  • the present invention provides a synthetic method of liraglutide using Fmoc-Gly-wang resin by solid phase peptide synthesis comprising the following steps of:
  • Step 1 Fluorenylmethoxycarbonyl-Glycine-Wang resin can be purchased directly from SigmaAldrich;
  • Step 2 The resin is swollen for 5 to 15 minutes under nitrogen in a mixture of DMF and ⁇ -valerolactone;
  • Step 3 Fluorenylmethoxycarbonyl chloride protecting group is removed under the following conditions: 20%of piperidine in DMF and ⁇ -valerolactone mixture for 10 to 20 minutes at 50°C-90°C;
  • Step 4 Preparation of fluorenylmethoxycarbonyl-Arginine (Pbf) -Glycine-Wang resin: the fluorenylmethoxycarbonyl-glycine-Wang resin obtained in step 1 is deprotected, washed with the mixture of DMF and ⁇ -valerolactone and Fmoc-L-Arg- (Pbf) -OH is subjected to a condensation reaction in the presence of the polypeptide coupling reagent to give fluorenylmethoxycarbonyl-Arginine (Pbf) -glycine-Wang resin;
  • Step 5 Preparation of fluorenylmethoxycarbonyl-Glycine-Arginine (Pbf) -Glycine-Wang resin: The Fmoc-dipeptide obtained in step 4 is deprotected and washed, and then reacted with Fmoc-Glycine-OH in the presence of the peptide coupling reagent to give fluorenylmethoxycarbonyl-glycine-Arginine (Pbf) -glycine-Wang resin;
  • Step 6 Preparation of fluorenylmethoxycarbonyl-Arginine (Pbf) -Glycine-Arginine (Pbf) -Glycine-Wang resin.
  • the resulting fluorenylmethoxycarbonyl-Glycine-Arginine (Pbf) -Glycine-Wang resin is deprotected, washed and Fmoc-L-Arginine (Pbf) -OH is added and then reacted in the presence of the peptide coupling reagent to give fluorenylmethoxycarbonyl-Arginine (Pbf) -Glycine-Arginine (Pbf) -Glycine-Wang resin;
  • Step 7 Preparation of fluorenylmethoxycarbonyl-Valine-Arginine (Pbf) -Glycine-Arginine (Pbf) -Glycine-Wang resin.
  • Fluorenylmethoxycarbonyl-Arginine (Pbf) -Glycine-Arginine (Pbf) -Glycine-Wang resin is deprotected, washed and then reacted with fluorenylmethoxycarbonyl-valine-OH in the presence of the polypeptide coupling reagent to obtain fluorenylmethoxycarbonyl-Valine-Arginine (Pbf) -Glycine-Arginine (Pbf) -Glycine-Wang resin;
  • Step 8 Preparation of fluorenylmethoxycarbonyl-Leucine-Valine-Arginine (Pbf) -Glycine-Arginine (Pbf) -Glycine-Wang resin. Fluorenylmethoxycarbonyl-Valine-Arginine (Pbf) -Glycine-Arginine (Pbf) -Glycine-Wang resin is deprotected, washed and fluorenylmethoxycarbonyl-leucine-OH is added in the presence of the peptide coupling reagent to give fluorenylmethoxycarbonyl-Leucine-Valine-Arginine (Pbf) -Glycine-Arginine (Pbf) -Glycine-Wang resin;
  • Step 9 Preparation of fluorenylmethoxycarbonyl-Tryptophane (Boc) -Leucine-Valine-Arginine (Pbf) -Glycine-Arginine (Pbf) -Glycine-Wang resin.
  • Step 10 Preparation of fluorenylmethoxycarbonyl-Alanine-Tryptophane (Boc) -Leucine-Valine-Arginine (Pbf) -Glycine-Arginine (Pbf) -Glycine-Wang resin.
  • Fmoc-L-Alanine-OH is added and subjected to a condensation reaction in the presence of a polypeptide coupling reagent to give fluorenylmethoxycarbonyl-Alanine-Tryptophane (Boc) -Leucine-Valine-Arginine (Pbf) -Glycine-Arginine (Pbf) -Glycine-Wang resin;
  • Step 11 Preparation of fluorenylmethoxycarbonyl-Isoleucine-Alanine-Tryptophane (Boc) -Leucine-Valine-Arginine (Pbf) -Glycine-Arginine (Pbf) -Glycine-Wang resin.
  • Step 12 Preparation of fluorenylmethoxycarbonyl-phenylalanine-Isoleucine-Alanine-Tryptophane (Boc) -Leucine-Valine-Arginine (Pbf) -Glycine-Arginine (Pbf) -Glycine-Wang resin.
  • the peptide obtained in step 11 is deprotected, washed and treated with fluorenylmethoxycarbonyl-Phenilalanine-OH to give fluorenylmethoxycarbonyl-phenylalanine-Isoleucine-Alanine-Tryptophane (Boc) -Leucine-Valine-Arginine (Pbf) -Glycine-Arginine (Pbf) -Glycine-Wang resin;
  • Step 13 Preparation of fluorenylmethoxycarbonyl-glutamic acid (OtBu) -phenylalanine-Isoleucine-Alanine-Tryptophane (Boc) -Leucine-Valine-Arginine (Pbf) -Glycine-Arginine (Pbf) -Glycine-Wang resin.
  • the peptide obtained in step 12 is deprotected, washed and treated with fluorenylmethoxycarbonyl-Glu (OtBu) -OH in the presence of a polypeptide coupling reagent to give fluorenylmethoxycarbonyl-glutamic acid (OtBu) -phenylalanine-Isoleucine-Alanine-Tryptophane (Boc) -Leucine-Valine-Arginine (Pbf) -Glycine-Arginine (Pbf) -Glycine-Wang resin;
  • Step 14 Preparation of Alloc-Lysine (fluorenylmethoxycarbonyl) -glutamic acid (OtBu) - phenylalanine-Isoleucine-Alanine-Tryptophane (Boc) -Leucine-Valine-Arginine (Pbf) -Glycine-Arginine (Pbf) -Glycine-Wang resin.
  • the peptide obtained in step 13 is deprotected, washed and treated with Alloc-Lysine (fluorenylmethoxycarbonyl) -OH in the presence of the peptide coupling reagent to give Alloc-Lysine (fluorenylmethoxycarbonyl) -glutamic acid (OtBu) -phenylalanine-Isoleucine-Alanine-Tryptophane (Boc) -Leucine-Valine-Arginine (Pbf) -Glycine-Arginine (Pbf) -Glycine-Wang resin;
  • the Alloc-Lysine (Fmoc) -OH can be replaced with Fmoc-Lys (Alloc) -OH, Fmoc-Lys (Mtt) -OH, Mtt-Lysine (Fmoc) -OH, Fmoc-Lysine (Dde) -OH, Dde-Lys (Fmoc) -OH and Fmoc-Lys (ivDde) -OH, so as to obtain side chains of lysine having different protecting groups.
  • Step 15 Preparation of Alloc-Lysine (fluorenylmethoxycarbonyl-Glutamic acid (Otbu) ) -glutamic acid (OtBu) -phenylalanine-Isoleucine-Alanine-Tryptophane (Boc) -Leucine-Valine-Arginine (Pbf) -Glycine-Arginine (Pbf) -Glycine-Wang resin.
  • the peptide obtained in step 14 is deprotected, washed and subjected to a condensation reaction with fluorenylmethoxycarbonyl-glutamic acid (OtBu) under conditions of a polypeptide coupling reagent to give Alloc-Lysine (fluorenylmethoxycarbonyl-Glutamic acid (Otbu) ) -glutamic acid (OtBu) -phenylalanine-Isoleucine-Alanine-Tryptophane (Boc) -Leucine-Valine-Arginine (Pbf) -Glycine-Arginine (Pbf) -Glycine-Wang resin;
  • Step 16 Preparation of Alloc-Lysine (Palmitic acid-Glutamic acid (Otbu) ) -glutamic acid (OtBu) -phenylalanine-Isoleucine-Alanine-Tryptophane (Boc) -Leucine-Valine-Arginine (Pbf) -Glycine-Arginine (Pbf) -Glycine-Wang resin.
  • Alloc-Lysine fluorenylmethoxycarbonyl-Glutamic acid (Otbu) ) -glutamic acid (OtBu) -phenylalanine-Isoleucine-Alanine-Tryptophane (Boc) -Leucine-Valine-Arginine (Pbf) -Glycine-Arginine (Pbf) -Glycine-Wang resin is deprotected, washed and Palmitic acid was added in the presence of the peptide coupling reagent to give Alloc-Lysine (Palmitic acid-Glutamic acid (Otbu) ) -glutamic acid (OtBu) -phenylalanine-Isoleucine-Alanine-Tryptophane (Boc) -Leucine-Valine-Arginine (Pbf) -Glycine-Arginine (Pbf) -Glycine-Wang resin;
  • Step 17 Preparation of NH2-Lysine (Palmitic acid-Glutamic acid (Otbu) ) -glutamic acid (OtBu) -phenylalanine-Isoleucine-Alanine- Tryptophane (Boc) -Leucine-Valine-Arginine (Pbf) -Glycine-Arginine (Pbf) -Glycine-Wang resin.
  • Alloc-Lysine (Palmitic acid-Glutamic acid (Otbu) ) -glutamic acid (OtBu) -phenylalanine-Isoleucine-Alanine-Tryptophane (Boc) -Leucine-Valine-Arginine (Pbf) -Glycine-Arginine (Pbf) -Glycine-Wang resin is washed and subjected to a Alloc deprotection reaction to generate a free amine group on the branching lysine;
  • Step 18 Preparation of fluorenylmethoxycarbonyl-alanine-Lysine (Palmitic acid-Glutamic acid (Otbu) ) -glutamic acid (OtBu) -phenylalanine-Isoleucine-Alanine-Tryptophane (Boc) -Leucine-Valine-Arginine (Pbf) -Glycine-Arginine (Pbf) -Glycine-Wang resin.
  • Step 19 Preparation of fluorenylmethoxycarbonyl-alanine-alanine-Lysine (Palmitic acid-Glutamic acid (Otbu) ) -glutamic acid (OtBu) -phenylalanine-Isoleucine-Alanine-Tryptophane (Boc) -Leucine-Valine-Arginine (Pbf) -Glycine-Arginine (Pbf) -Glycine-Wang resin.
  • Fluorenylmethoxycarbonyl-alanine-Lysine (Palmitic acid-Glutamic acid (Otbu) ) -glutamic acid (OtBu) -phenylalanine-Isoleucine-Alanine-Tryptophane (Boc) -Leucine-Valine-Arginine (Pbf) -Glycine-Arginine (Pbf) -Glycine-Wang resin is deprotected, washed and fluorenylmethoxycarbonyl-alanine-OH is added in a polypeptide coupling reagent conditions, to give fluorenylmethoxycarbonyl-alanine-alanine-Lysine (Palmitic acid-Glutamic acid (Otbu) ) -glutamic acid (OtBu) -phenylalanine-Isoleucine-Alanine-Tryptophane (Boc) -Leucine-Valine-Arg
  • Step 20 Preparation of fluorenylmethoxycarbonyl-Gln (Trt) -alanine-alanine-Lysine (Palmitic acid-Glutamic acid (Otbu) ) -glutamic acid (OtBu) -phenylalanine-Isoleucine-Alanine-Tryptophane (Boc) -Leucine-Valine-Arginine (Pbf) -Glycine-Arginine (Pbf) -Glycine-Wang resin.
  • Fluorenylmethoxycarbonyl-alanine-alanine-Lysine (Palmitic acid-Glutamic acid (Otbu) ) - glutamic acid (OtBu) -phenylalanine-Isoleucine-Alanine-Tryptophane (Boc) -Leucine-Valine-Arginine (Pbf) -Glycine-Arginine (Pbf) -Glycine-Wang resin is deprotected, washed and fluorenylmethoxycarbonyl-Gln (Trt) -OH is added in a peptide coupling reagent conditions, to give fluorenylmethoxycarbonyl-Gln (Trt) -alanine-alanine-Lysine (Palmitic acid-Glutamic acid (Otbu) ) -glutamic acid (OtBu) -phenylalanine-Isoleucine-Alanine-T
  • Step 21 Preparation of fluorenylmethoxycarbonyl-Gly-Gln (Trt) -alanine-alanine-Lysine (Palmitic acid-Glutamic acid (Otbu) ) -glutamic acid (OtBu) -phenylalanine-Isoleucine-Alanine-Tryptophane (Boc) -Leucine-Valine-Arginine (Pbf) -Glycine-Arginine (Pbf) -Glycine-Wang resin.
  • Step 22 Preparation of fluorenylmethoxycarbonyl-Glu (OtBu) -Gly-Gln (Trt) -alanine-alanine-Lysine (Palmitic acid-Glutamic acid (Otbu) ) -glutamic acid (OtBu) -phenylalanine-Isoleucine-Alanine-Tryptophane (Boc) -Leucine-Valine-Arginine (Pbf) -Glycine-Arginine (Pbf) -Glycine-Wang resin.
  • Step 23 Preparation of Fluorenylmethoxycarbonyl-Leu-Glu (OtBu) -Gly-Gln (Trt) -alanine- alanine-Lysine (Palmitic acid-Glutamic acid (Otbu) ) -glutamic acid (OtBu) -phenylalanine-Isoleucine-Alanine-Tryptophane (Boc) -Leucine-Valine-Arginine (Pbf) -Glycine-Arginine (Pbf) -Glycine-Wang resin.
  • Step 24 Preparation of Fluorenylmethoxycarbonyl-Tyr (tBu) -Leu-Glu (OtBu) -Gly-Gln (Trt) -alanine-alanine-Lysine (Palmitic acid-Glutamic acid (Otbu) ) -glutamic acid (OtBu) -phenylalanine-Isoleucine-Alanine-Tryptophane (Boc) -Leucine-Valine-Arginine (Pbf) -Glycine-Arginine (Pbf) -Glycine-Wang resin.
  • Fluorenylmethoxycarbonyl-Leu-Glu (OtBu) -Gly-Gln (Trt) -alanine-alanine-Lysine (Palmitic acid-Glutamic acid (Otbu) ) -glutamic acid (OtBu) -phenylalanine-Isoleucine-Alanine-Tryptophane (Boc) -Leucine-Valine-Arginine (Pbf) -Glycine-Arginine (Pbf) -Glycine-Wang resin is deprotected, washed and fluorenylmethoxycarbonyl-Tyr (tBu) -OH is added in a peptide coupling reagent conditions, to give Fluorenylmethoxycarbonyl-Tyr (tBu) -Leu-Glu (OtBu) -Gly-Gln (Trt) -alanine-alanine-Lysine (P
  • Step 25 Preparation of Fluorenylmethoxycarbonyl-Ser (tBu) -Tyr (tBu) -Leu-Glu (OtBu) -Gly-Gln (Trt) -alanine-alanine-Lysine (Palmitic acid-Glutamic acid (Otbu) ) -glutamic acid (OtBu) -phenylalanine-Isoleucine-Alanine-Tryptophane (Boc) -Leucine-Valine-Arginine (Pbf) -Glycine-Arginine (Pbf) -Glycine-Wang resin.
  • Step 26 Preparation of Fluorenylmethoxycarbonyl-Ser (tBu) -Ser (tBu) -Tyr (tBu) -Leu-Glu (OtBu) -Gly-Gln (Trt) -alanine-alanine-Lysine (Palmitic acid-Glutamic acid (Otbu) ) -glutamic acid (OtBu) -phenylalanine-Isoleucine-Alanine-Tryptophane (Boc) -Leucine-Valine-Arginine (Pbf) -Glycine-Arginine (Pbf) -Glycine-Wang resin.
  • Step 27 Preparation of Fluorenylmethoxycarbonyl-Val-Ser (tBu) -Ser (tBu) -Tyr (tBu) -Leu-Glu (OtBu) -Gly-Gln (Trt) -alanine-alanine-Lysine (Palmitic acid-Glutamic acid (Otbu) ) -glutamic acid (OtBu) -phenylalanine-Isoleucine-Alanine-Tryptophane (Boc) -Leucine-Valine-Arginine (Pbf) -Glycine-Arginine (Pbf) -Glycine-Wang resin.
  • Step 28 Preparation of Fluorenylmethoxycarbonyl-Asp (OtBu) -Val-Ser (tBu) -Ser (tBu) -Tyr (tBu) -Leu-Glu (OtBu) -Gly-Gln (Trt) -alanine-alanine-Lysine (Palmitic acid-Glutamic acid (Otbu) ) -glutamic acid (OtBu) -phenylalanine-Isoleucine-Alanine- Tryptophane (Boc) -Leucine-Valine-Arginine (Pbf) -Glycine-Arginine (Pbf) -Glycine-Wang resin.
  • Step 29 Preparation of Fluorenylmethoxycarbonyl-Ser (tBu) -Asp (OtBu) -Val-Ser (tBu) -Ser (tBu) -Tyr (tBu) -Leu-Glu (OtBu) -Gly-Gln (Trt) -alanine-alanine-Lysine (Palmitic acid-Glutamic acid (Otbu) ) -glutamic acid (OtBu) -phenylalanine-Isoleucine-Alanine-Tryptophane (Boc) -Leucine-Valine-Arginine (Pbf) -Glycine-Arginine (Pbf) -Glycine-Wang resin.
  • Fluorenylmethoxycarbonyl-Asp (OtBu) -Val-Ser (tBu) -Ser (tBu) -Tyr (tBu) -Leu-Glu (OtBu) -Gly-Gln (Trt) -alanine-alanine-Lysine (Palmitic acid-Glutamic acid (Otbu) ) -glutamic acid (OtBu) -phenylalanine-Isoleucine-Alanine-Tryptophane (Boc) -Leucine-Valine-Arginine (Pbf) -Glycine-Arginine (Pbf) -Glycine-Wang resin is deprotected, washed and fluorenylmethoxycarbonyl-Ser (tBu) -OH is added in a peptide coupling reagent conditions, to give Fluorenylmethoxycarbonyl-Ser (tBu) -Asp
  • Step 30 Preparation of Fluorenylmethoxycarbonyl-Thr (tBu) -Ser (tBu) -Asp (OtBu) -Val-Ser (tBu) -Ser (tBu) -Tyr (tBu) -Leu-Glu (OtBu) -Gly-Gln (Trt) -alanine-alanine-Lysine (Palmitic acid-Glutamic acid (Otbu) ) -glutamic acid (OtBu) -phenylalanine-Isoleucine-Alanine-Tryptophane (Boc) -Leucine-Valine-Arginine (Pbf) -Glycine-Arginine (Pbf) -Glycine-Wang resin.
  • Step 31 Preparation of Fluorenylmethoxycarbonyl-Phe-Thr (tBu) -Ser (tBu) -Asp (OtBu) -Val-Ser (tBu) -Ser (tBu) -Tyr (tBu) -Leu-Glu (OtBu) -Gly-Gln (Trt) -alanine-alanine-Lysine (Palmitic acid-Glutamic acid (Otbu) ) -glutamic acid (OtBu) -phenylalanine-Isoleucine-Alanine-Tryptophane (Boc) -Leucine-Valine-Arginine (Pbf) -Glycine-Arginine (Pbf) -Glycine-Wang resin.
  • Step 32 Preparation of Fluorenylmethoxycarbonyl-Thr (tBu) -Phe-Thr (tBu) -Ser (tBu) -Asp (OtBu) -Val-Ser (tBu) -Ser (tBu) -Tyr (tBu) -Leu-Glu (OtBu) -Gly-Gln (Trt) -alanine-alanine-Lysine (Palmitic acid-Glutamic acid (Otbu) ) -glutamic acid (OtBu) -phenylalanine-Isoleucine-Alanine-Tryptophane (Boc) -Leucine-Valine-Arginine (Pbf) -Glycine-Arginine (Pbf) -Glycine-Wang resin.
  • Step 33 Preparation of Fluorenylmethoxycarbonyl-Gly-Thr (tBu) -Phe-Thr (tBu) -Ser (tBu) -Asp (OtBu) -Val-Ser (tBu) -Ser (tBu) -Tyr (tBu) -Leu-Glu (OtBu) -Gly-Gln (Trt) -alanine-alanine-Lysine (Palmitic acid-Glutamic acid (Otbu) ) -glutamic acid (OtBu) -phenylalanine-Isoleucine-Alanine-Tryptophane (Boc) -Leucine-Valine-Arginine (Pbf) -Glycine-Arginine (Pbf) -Glycine-Wang resin.
  • Step 34 Preparation of Fluorenylmethoxycarbonyl-Glu (OtBu) -Gly-Thr (tBu) -Phe-Thr (tBu) -Ser (tBu) -Asp (OtBu) -Val-Ser (tBu) -Ser (tBu) -Tyr (tBu) -Leu-Glu (OtBu) -Gly-Gln (Trt) -alanine-alanine-Lysine (Palmitic acid-Glutamic acid (Otbu) ) -glutamic acid (OtBu) -phenylalanine-Isoleucine-Alanine-Tryptophane (Boc) -Leucine-Valine-Arginine (Pbf) -Glycine-Arginine (Pbf) -Glycine-Wang resin.
  • Step 35 Preparation of Fluorenylmethoxycarbonyl-Ala-Glu (OtBu) -Gly-Thr (tBu) -Phe-Thr (tBu) -Ser (tBu) -Asp (OtBu) -Va l-Ser (tBu) -Ser (tBu) -Tyr (tBu) -Leu-Glu (OtBu) -Gly-Gln (Trt) -alanine-alanine-Lysine (Palmitic acid-Glutamic acid (Otbu) ) -glutamic acid (OtBu) -phenylalanine-Isoleucine-Alanine-Tryptophane (Boc) -Leucine-Valine-Arginine (Pbf) -Glycine-Arginine (Pbf) -Glycine-Wang resin.
  • Fluorenylmethoxycarbonyl-Glu (OtBu) -Gly-Thr (tBu) -Phe-Thr (tBu) -Ser (tBu) -Asp (OtBu) -Val-Ser (tBu) -Ser (tBu) -Tyr (tBu) -Leu-Glu (OtBu) -Gly-Gln (Trt) -alanine-alanine-Lysine (Palmitic acid-Glutamic acid (Otbu) ) -glutamic acid (OtBu) -phenylalanine-Isoleucine-Alanine-Tryptophane (Boc) -Leucine-Valine-Arginine (Pbf) -Glycine-Arginine (Pbf) -Glycine-Wang resin is deprotected, washed and fluorenylmethoxycarbonyl-Ala-OH is added in a peptide coup
  • Step 36 Preparation of Fluorenylmethoxycarbonyl-His (Trt) -Ala-Glu (OtBu) -Gly-Thr (tBu) -Phe-Thr (tBu) -Ser (tBu) -Asp (OtBu) -Val-Ser (tBu) -Ser (tBu) -Tyr (tBu) -Leu-Glu (OtBu) -Gly-Gln (Trt) -alanine-alanine-Lysine (Palmitic acid-Glutamic acid (Otbu) ) -glutamic acid (OtBu) -phenylalanine-Isoleucine-Alanine-Tryptophane (Boc) -Leucine-Valine-Arginine (Pbf) -Glycine-Arginine (Pbf) -Glycine-Wang resin.
  • Fluorenylmethoxycarbonyl-Ala-Glu (OtBu) -Gly-Thr (tBu) -Phe-Thr (tBu) -Ser (tBu) -Asp (OtBu) -Val-Ser (tBu) -Ser (tBu) -Tyr (tBu) -Leu-Glu (OtBu) -Gly-Gln (Trt) -alanine-alanine-Lysine
  • Step 37 The peptide anchored to the solid support is cleaved with a mixture of TFA/H 2 O/TIS 95: 2.5: 2.5.
  • the cleavage solution is precipitated with diethyl ether and centrifuged at 3500-5000 rpm to give a white precipitate.
  • the precipitate is washed and centrifuged with diethyl ether for another three times to give a final precipitate;
  • Step 38 The crude liraglutide is purified by Preparative-HPLC;
  • Step 39 The purified Liraglutide solution is lyophilized by lyophilizer at a temperature between -50°C to -70°C for 18-48 hours to give prepared liraglutide more than 98%purity.
  • the conventional method of SPPS for the synthesis of liraglutide is usually not environmentally friendly due to the use of a large amount of DMF.
  • the method of the invention is a green and environment friendly synthetic method due to the use of ⁇ -valerolactone to substitute 60%-90%of DMF.
  • the conventional method of SPPS for the synthesis of liraglutide is generally carried out under a lower temperature of 20 to 30°C.
  • the present method is carried out under a higher temperature of 50 to 90°C and thus has a faster reaction rate than the conventional SPPS process, produces less amount of waste and allows to obtain liraglutide with a high yield.
  • the present method is a one-pot method and is continuously carried out in a reactor.
  • Example 1 Synthesis of Liraglutide using Fmoc-Gly-wang resin with a loading degree of 0.47 mmol/g and Alloc-Lysine (Fmoc) -OH as a branching lysine.
  • the synthesis scale was 100 mmol and 250 mmol amino acids were used.
  • Fmoc-Arg (Pbf) -OH Fmoc-Arg (Pbf) -OH, coupling reagent mixture were added in the reactor.
  • the above Fmoc de-protection step was repeated as mentioned above and corresponding amino acid couplings were performed twice at 90°C for 10 minutes.
  • the following amino acids were used: Fmoc-Gly-OH, Fmoc-Arg (Pbf) -OH, Fmoc-Val-OH, Fmoc-Leu-OH, Fmoc-Trp (Boc) -OH, Fmoc-Ala-OH, Fmoc-Ile-OH, Fmoc-Phe-OH, Fmoc-Glu (OtBu) -OH, Alloc-Lys (Fmoc) -OH.
  • Fmoc deprotection was performed as mentioned above and Fmoc-Glu-OtBu and palmitic acid were coupled one by one to the lysine.
  • a tetra coupling performed at 75°C was chosen.
  • Alloc deprotection was performed as described before and Liraglutide backbone was grown to the main chain of the lysine with the following amino acids: Fmoc-Ala-OH, Fmoc-Ala-OH, Fmoc-Gln (Trt) -OH, Fmoc-Gly-OH, Fmoc-Glu (OtBu) -OH, Fmoc-Leu-OH, Fmoc-Tyr (tBu) -OH, Fmoc-Ser (tBu) -OH, Fmoc-Ser (tBu) -OH, Fmoc-Val-OH, Fmoc-Asp (OtBu) -OH, Fmoc-Ser
  • the linear liraglutide wang resin was washed for 3 times by DMF and ⁇ -valerolactone mixture for subsequent synthesis reaction.
  • the peptide was cleaved from the solid support with a mixture of TFA/TIS/H 2 O 95: 2.5: 2.5 for 3 hours and precipitated in cold TBME.
  • the precipitate was washed with TBME for 5 times and centrifuged with a speed of 3500 rpm for 10 minutes each centrifugation.
  • the precipitate was dried under vacuum and dissolved in water/acetonitrile at pH 7.8.
  • the crude yield was analyzed by LC-MS with a final yield of 67%.
  • the crude Liraglutide crude is purified by Preparative-HPLC; then the purified Liraglutide solution is lyophilized by lyophilizer at a temperature of -50°C for 18 hours to give prepared liraglutide having a high purity, as shown in Figure 2.
  • EXAMPLE 2 Synthesis of Liraglutide using Fmoc-Gly-2-CTC Resin with a Substitution Degree of 0.47 mmol/g and Dde-Lys (Fmoc) -OH as a branching lysine.
  • the synthesis scale was 100 mmol and 250 mmol amino acids were used.
  • Fmoc deprotection was performed as mentioned above and Fmoc-Glu-OtBu and palmitic acid were coupled one by one to the lysine.
  • a tetra coupling performed at 75°C was chosen.
  • Dde deportection was performed with a solution of 2%of hydrazine monohydrate in DMF and this method was repeated 3 times.
  • Liraglutide backbone was grown to the main chain of the lysine with the following amino acids: Fmoc-Ala-OH, Fmoc-Ala-OH, Fmoc-Gln (Trt) -OH, Fmoc-Gly-OH, Fmoc-Glu (OtBu) -OH, Fmoc-Leu-OH, Fmoc-Tyr (tBu) -OH, Fmoc-Ser (tBu) -OH, Fmoc-Ser (tBu) -OH, Fmoc-Val-OH, Fmoc-Asp (OtBu) -OH, Fmoc-Ser (tBu) -OH, Fmoc-Thr (tBu) -OH, Fmoc-Phe-OH, Fmoc-Thr (tBu) -OH, Fmoc-Gly-OH, Fmoc-Glu (OtBu) -OH, Fmoc-Ala-
  • the linear Liraglutide resin was washed for 3 times by DMF and ⁇ -valerolactone mixture for subsequent synthesis reaction.
  • the peptide was cleaved from the solid support with a mixture of TFA/TIS/H 2 O 95: 2.5: 2.5 for 3 hours and precipitated in cold TBME.
  • the precipitate was washed with TBME for 5 times and centrifuged with a speed of 3500 rpm for 10 minutes each centrifugation.
  • the precipitate was washed with TBME for 5 times and centrifuged with a speed of 3500 rpm for 10 minutes each centrifugation.
  • the precipitate was dried under vacuum and dissolved at pH 7.8.
  • the crude yield was analyzed by LC-MS with a final yield of 71%.
  • the crude Liraglutide crude is purified by Preparative-HPLC; then the purified Liraglutide solution is lyophilized by lyophilizer at a temperature of -70°C for 48 hours to give prepared liraglutide having a high purity, as shown in Figure 4.
  • EXAMPLE 3 Synthesis of Liraglutide using Fmoc-Gly-wang resin Resin with a Substitution Degree of 0.47 mmol/g and Fmoc-Lysine (Mtt) -OH as a branching lysine.
  • the synthesis scale was 100 mmol and 250 mmol amino acids were used.
  • Fmoc deprotection was performed as mentioned above and Liraglutide backbone was grown to the main chain of the lysine with the following amino acids: Fmoc-Ala-OH, Fmoc-Ala-OH, Fmoc-Gln (Trt) -OH, Fmoc-Gly-OH, Fmoc-Glu (OtBu) -OH, Fmoc-Leu-OH, Fmoc-Tyr (tBu) -OH, Fmoc-Ser (tBu) -OH, Fmoc-Ser (tBu) -OH, Fmoc-Val-OH, Fmoc-Asp (OtBu) -OH, Fmoc-Ser (tBu) -OH, Fmoc-Thr (tBu) -OH, Fmoc-Phe-OH, Fmoc-Thr (tBu) -OH, Fmoc-Gly-OH, Fmoc-Glu (Ot
  • Mtt was deprotected with a mixture of TFA/TIS/DCM and Fmoc-Glu-OtBu and palmitic acid were coupled one by one to the lysine.
  • the peptide was cleaved from the solid support with a mixture of TFA/TIS/H 2 O 95: 2.5: 2.5 for 3 hours and precipitated in cold TBME.
  • the precipitate was washed with TBME for 5 times and centrifuged with a speed of 3500 rpm for 10 minutes each centrifugation.
  • the precipitate was dried under vacuum and dissolved at pH 7.8.
  • the crude yield was analysed by LC-MS with a final yield of 51%.
  • the crude Liraglutide crude is purified by Preparative-HPLC; then the purified Liraglutide solution is lyophilized by lyophilizer at a temperature of -60°C for 30 hours to give prepared liraglutide having a high purity, as shown in Figure 5.
  • EXAMPLE 4 Synthesis of Liraglutide using Fmoc-Gly-wang resin Resin with a Substitution Degree of 0.47 mmol/g and Fmoc-Lysine (ivDde) -OH as a branching lysine.
  • the synthesis scale was 100 mmol and 250 mmol amino acids were used.
  • Fmoc deprotection was performed as mentioned above and Liraglutide backbone was grown to the main chain of the lysine with the following amino acids: Fmoc-Ala-OH, Fmoc-Ala-OH, Fmoc-Gln (Trt) -OH, Fmoc-Gly-OH, Fmoc-Glu (OtBu) -OH, Fmoc-Leu-OH, Fmoc-Tyr (tBu) -OH, Fmoc-Ser (tBu) -OH, Fmoc-Ser (tBu) -OH, Fmoc-Val-OH, Fmoc-Asp (OtBu) -OH, Fmoc-Ser (tBu) -OH, Fmoc-Thr (tBu) -OH, Fmoc-Phe-OH, Fmoc-Thr (tBu) -OH, Fmoc-Gly-OH, Fmoc-Glu (Ot
  • IvDde was deprotected as mentioned above and Fmoc-Glu-OtBu and palmitic acid were coupled one by one to the lysine.
  • the linear Liraglutide wang resin was washed for 3 times.
  • the peptide was cleaved from the solid support with a mixture of TFA/TIS/H 2 O 95: 2.5: 2.5 for 3 hours and precipitated in cold TBME.
  • the precipitate was washed with TBME for 5 times and centrifuged with a speed of 3500 rpm for 10 minutes each centrifugation.
  • the precipitate was dried under vacuum and dissolved at pH 7.8.
  • the crude yield was analyzed by LC-MS with a final yield of 45%.
  • the crude Liraglutide crude is purified by Preparative-HPLC; then the purified Liraglutide solution is lyophilized by lyophilizer at a temperature of -55°C for 24 hours to give prepared liraglutide having a high purity, as shown in Figure 6.
  • EXAMPLE 5 Synthesis of Liraglutide using Fmoc-Gly-wang resin Resin with a loading Degree of 0.47 mmol/g and Dde-Lysine (Fmoc) -OH as a branching lysine.
  • the synthesis scale was 100 mmol and 250 mmol amino acids were used.
  • Liraglutide backbone was grown to the main chain of the lysine with the following amino acids: Fmoc-Ala-OH, Fmoc-Ala-OH, Fmoc-Gln (Trt) -OH, Fmoc-Gly-OH, Fmoc-Glu (OtBu) -OH, Fmoc-Leu-OH, Fmoc-Tyr (tBu) -OH, Fmoc-Ser (tBu) -OH, Fmoc-Ser (tBu) -OH, Fmoc-Val-OH, Fmoc-Asp (OtBu) -OH, Fmoc-Ser (tBu) -OH, Fmoc-Thr (tBu) -OH, Fmoc-Phe-OH, Fmoc-Thr (tBu) -OH, Fmoc-Gly-OH, Fmoc-Glu (OtBu) -OH, Fmoc-Ala-
  • the linear Liraglutide wang resin was washed for 3 times with the same mixture used above.
  • the peptide was cleaved from the solid support with a mixture of TFA/TIS/H 2 O 95: 2.5: 2.5 for 3 hours and precipitated in cold TBME.
  • the precipitate was washed with TBME for 5 times and centrifuged.
  • the precipitate was dried under vacuum and dissolved at pH 7.8.
  • the crude yield was analyzed by LC-MS with a final yield of 73%.
  • the crude Liraglutide crude is purified by Preparative-HPLC; then the purified Liraglutide solution is lyophilized by lyophilizer at a temperature of -65°C for 36 hours to give prepared liraglutide having a high purity, as shown in Figure 7.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne un procédé de préparation de liraglutide par synthèse de peptides en phase solide, le procédé utilisant une résine Fmoc-Gly ayant un groupe protecteur Fmoc en tant que support pour la synthèse de peptides en phase solide, et après achèvement de la réaction de déprotection du groupe protecteur Fmoc, chacune des réactions dans la synthèse de peptides en phase solide de liraglutide est lavée avec un mélange de DMF et de γ-valérolactone à plusieurs reprises, de préférence 2 à 3 fois.
PCT/CN2019/095783 2019-07-12 2019-07-12 Procédé de préparation de liraglutide par synthèse de peptides en phase solide WO2021007703A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/CN2019/095783 WO2021007703A1 (fr) 2019-07-12 2019-07-12 Procédé de préparation de liraglutide par synthèse de peptides en phase solide

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2019/095783 WO2021007703A1 (fr) 2019-07-12 2019-07-12 Procédé de préparation de liraglutide par synthèse de peptides en phase solide

Publications (1)

Publication Number Publication Date
WO2021007703A1 true WO2021007703A1 (fr) 2021-01-21

Family

ID=74210118

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2019/095783 WO2021007703A1 (fr) 2019-07-12 2019-07-12 Procédé de préparation de liraglutide par synthèse de peptides en phase solide

Country Status (1)

Country Link
WO (1) WO2021007703A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116284206A (zh) * 2023-05-18 2023-06-23 杭州湃肽生化科技有限公司 一种树脂材料的洗涤方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102286092A (zh) * 2011-09-14 2011-12-21 深圳翰宇药业股份有限公司 利拉鲁肽的固相合成方法
CN103087181A (zh) * 2013-01-17 2013-05-08 刘卫 一种利拉鲁肽的固相合成方法
CN103980358A (zh) * 2014-01-03 2014-08-13 杭州诺泰制药技术有限公司 一种制备利拉鲁肽的方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102286092A (zh) * 2011-09-14 2011-12-21 深圳翰宇药业股份有限公司 利拉鲁肽的固相合成方法
CN103087181A (zh) * 2013-01-17 2013-05-08 刘卫 一种利拉鲁肽的固相合成方法
CN103980358A (zh) * 2014-01-03 2014-08-13 杭州诺泰制药技术有限公司 一种制备利拉鲁肽的方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JAD，Y.E.ET AL.: "Green Solid-Phase Peptide Synthesis (GSPPS) 3. Green Solvents for Fmoc Removal in Peptide Chemistry", ORGANIC PROCESS RESEARCH & DEVELOPMENT, vol. 21, 30 January 2017 (2017-01-30), XP055774092, DOI: 20200320123217Y *
KUMAR，A. ET AL.: "Troubleshooting When Using γ‑Valerolactone (GVL) in Green Solid-Phase Peptide Synthesis", ORGANIC PROCESS RESEARCH & DEVELOPMENT, vol. 23, 3 April 2019 (2019-04-03), XP055774095, DOI: 20200320124053Y *
LI，C.X. ET AL.: "Solid phase synthesis and identification of liraglutide", PRAC. J. MED. & PHARM., vol. 35, no. 6, 30 June 2018 (2018-06-30), DOI: 20200320124312Y *
MA，Y.C. ET AL.: "Preparation of Liraglutide", CHINESE JOURNAL OF PHARMACEUTICALS, vol. 44, no. 2, 31 December 2013 (2013-12-31), pages 122 - 123, DOI: 20200320124443Y *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116284206A (zh) * 2023-05-18 2023-06-23 杭州湃肽生化科技有限公司 一种树脂材料的洗涤方法
CN116284206B (zh) * 2023-05-18 2023-08-15 杭州湃肽生化科技有限公司 一种树脂材料的洗涤方法

Similar Documents

Publication Publication Date Title
EP3398960B1 (fr) Procédé de préparation du semaglutide
CN106699871B (zh) 一种利拉鲁肽的制备方法
RU2766331C2 (ru) Синтез лираглутида
WO2014199397A2 (fr) Procédé pour la préparation de liraglutide
KR20100036326A (ko) 프람린타이드의 생산 방법
WO2023089594A1 (fr) Procédé de préparation de tirzépatide ou de sel pharmaceutiquement acceptable de celui-ci
EP3414257B1 (fr) Procédé de préparation de liraglutide à l'aide d'un lieur bal
EP3405476B1 (fr) Procédé de préparation de peptides avec un lieur pswang
CN112111001B (zh) 胸腺肽Tα-1的合成方法
CN106632655B (zh) 一种艾塞那肽的制备方法及其产品
KR20210102362A (ko) 플레카나타이드의 개선된 제조 방법
WO2021007703A1 (fr) Procédé de préparation de liraglutide par synthèse de peptides en phase solide
CN113754753A (zh) 一种索玛鲁肽的合成方法
WO2021007701A1 (fr) Procédé de préparation de liraglutide par synthèse de peptides en phase solide
WO2023196765A1 (fr) Procédé de préparation d'un agoniste double de glp-1/glucagon
EP3196207A1 (fr) Procédé de préparation de peptides à liaison pswang
WO2006105199A2 (fr) Compositions et methodes de synthese d'un peptide et d'un conjugue apparente
EP3398959B1 (fr) Méthode de préparation du lixisénatide
CN114805480A (zh) 一种奥曲肽的制备方法
AU2007248855A1 (en) Composition and method for the release of protected peptides from a resin
CN114057829A (zh) 一种n-甲基化多肽的固相合成方法
WO2022144860A1 (fr) Synthèse de téduglutide
WO2023105497A1 (fr) Synthèse d'analogues de glp-1
CN118047852A (zh) 一种制备替泽帕肽的方法
KR20230167199A (ko) 펩타이드 정제방법 및 그를 이용하여 정제된 펩타이드

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19937554

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19937554

Country of ref document: EP

Kind code of ref document: A1